Access to hepatitis C testing and treatment for people who inject drugs and people in prisons – a global perspective. Policy brief
ThisWHO pol icy brief highlights that people who inject drugs (PWID) and prisoners are disproportionately affected by hepatitis C (HCV), with 23% of new infections and one in three deaths linked to injection drug use. It urges expanded access to testing, harm reduction services, and direct-acting antiviral (DAA) treatment to meet 2030 elimination targets